SCHEMBL2977917

SCHEMBL2977917

Cc1cccc2snc(Br)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
AURKA O14965 1/20 0.35
ROCK2 O75116 1/20 0.35
CSF1R P07333 1/20 0.35
FGFR1 P11362 1/20 0.35
FLT1 P17948 1/20 0.35
RPS6KB1 P23443 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
FLT3 P36888 1/20 0.35
RPS6KA3 P51812 1/20 0.35
ROCK1 Q13464 1/20 0.35
AURKB Q96GD4 1/20 0.35
PLK3 Q9H4B4 1/20 0.35
MAPT P10636 6/20 0.34
BRPF1 P55201 1/20 0.34
KDM4E B2RXH2 2/20 0.33
TP53 P04637 4/20 0.32
LMNA P02545 2/20 0.32
KCNA5 P22460 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8404470 0.79 ALDH1A1 (0.37) ALDH1A1AURKAROCK2CSF1RFGFR1
SCHEMBL31165845 0.72 ALDH1A1 (0.33) ALDH1A1MAPTKDM4EEPAS1HSD17B10
SCHEMBL14352993 0.68 CYP2A6 (0.41) ALDH1A1KDM4ELMNAHSD17B10CYP1A2
SCHEMBL6327715 0.67 ALDH1A1 (0.41) ALDH1A1MAPTCYP1A2CYP2A6
SCHEMBL2428372 0.66 SCN4A (0.33) ALDH1A1LMNACYP1A2
SCHEMBL4160530 0.66 ALDH1A1 (0.43) ALDH1A1MAPTBRPF1LMNAGPR84
SCHEMBL4204967 0.66 MAPT (0.56) ALDH1A1MAPTKDM4ETP53EPAS1
SCHEMBL31722153 0.64 HSD17B10 (0.48) ALDH1A1AURKAROCK2CSF1RFGFR1
SCHEMBL13090010 0.63 ELANE (0.39) CYP1A2CYP2A6
SCHEMBL14127197 0.61 ALDH1A1 (0.63) ALDH1A1MAPTKDM4ETP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
US-7776847-B2 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2010-08-17 US disclosed
EP-1853573-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION Rigel Pharmaceuticals, Inc. (US) 2007-11-14 EP disclosed
US-20060229294-A1 Benzisothiazoles useful for treating or preventing HCV infection RIGEL PHARMACEUTICALS, INC. (US) 2006-10-12 US disclosed
WO-2006091858-A1 BENZISOTHIAZOLES USEFUL FOR TREATING OR PREVENTING HCV INFECTION RIGEL PHARMACEUTICALS, INC. (US) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229294-A1 Benzisothiazoles useful for treating or preventing HCV infection HAVCR2, ZC3HAV1, MAVS ALDH1A1 227/4885AURKA 3467/4885ROCK2 3235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.